|
US5268454A
(en)
*
|
1991-02-08 |
1993-12-07 |
La Jolla Pharmaceutical Company |
Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
|
|
KR100361933B1
(ko)
*
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
|
US6410775B1
(en)
*
|
1995-06-07 |
2002-06-25 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
|
US5874409A
(en)
|
1995-06-07 |
1999-02-23 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
|
EP0954531A1
(en)
*
|
1996-06-06 |
1999-11-10 |
Lajolla Pharmaceutical Company |
aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
|
|
US5817752A
(en)
*
|
1996-06-06 |
1998-10-06 |
La Jolla Pharmaceutical Company |
Cyclic polypeptides comprising a thioether linkage and methods for their preparation
|
|
US6812327B1
(en)
*
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
US8212004B2
(en)
*
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
US6858210B1
(en)
|
1998-06-09 |
2005-02-22 |
La Jolla Pharmaceutical Co. |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
|
|
IL126447A
(en)
*
|
1998-10-04 |
2004-09-27 |
Vascular Biogenics Ltd |
An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
|
|
US20050197283A1
(en)
*
|
1998-10-04 |
2005-09-08 |
Vascular Biogenics Ltd. |
Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
|
|
US20010010818A1
(en)
*
|
1998-12-09 |
2001-08-02 |
Engle Steven B. |
Methods and formulations for reducing circulating antibodies
|
|
US6399578B1
(en)
*
|
1998-12-09 |
2002-06-04 |
La Jolla Pharmaceutical Company |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
|
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
|
CA2376057A1
(en)
*
|
1999-06-08 |
2000-12-14 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising aminooxy groups
|
|
AUPQ272699A0
(en)
*
|
1999-09-09 |
1999-09-30 |
Unisearch Limited |
Use of beta2GPI in diagnostic tests for autoimmune diseases
|
|
CN1399562A
(zh)
|
1999-11-28 |
2003-02-26 |
拉卓拉药物公司 |
基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
|
|
PT2857516T
(pt)
*
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
CA2414076A1
(en)
|
2000-06-08 |
2001-12-13 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
|
US7879328B2
(en)
*
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
AU2001268427B2
(en)
*
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
EP2267017A3
(en)
*
|
2000-08-18 |
2011-07-06 |
Human Genome Sciences, Inc. |
Binding polypeptides for B lymphocyte stimulator protein (BLyS)
|
|
AU2001288301A1
(en)
*
|
2000-08-18 |
2002-03-04 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
JP2005515754A
(ja)
*
|
2001-05-30 |
2005-06-02 |
ジーン セラピー システムズ インコーポレーテッド |
タンパク質アレイ、ならびにそれらを生産する方法およびシステム
|
|
KR100985457B1
(ko)
|
2001-06-21 |
2010-10-06 |
다이나박스 테크놀로지 코퍼레이션 |
키메라 면역조절 화합물 및 그것들의 사용 방법
|
|
US20030114405A1
(en)
*
|
2001-08-13 |
2003-06-19 |
Linnik Matthew D. |
Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
|
|
US7105135B2
(en)
*
|
2001-10-16 |
2006-09-12 |
Lockheed Martin Corporation |
System and method for large scale detection of hazardous materials in the mail or in other objects
|
|
US7771951B2
(en)
*
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
|
US20030175760A1
(en)
*
|
2001-12-03 |
2003-09-18 |
Walker Wynn L. |
Discovery of therapeutic products
|
|
WO2003048730A2
(en)
*
|
2001-12-03 |
2003-06-12 |
Abgenix, Inc. |
Identification of high affinity molecules by limited dilution screening
|
|
AU2003237870A1
(en)
*
|
2002-06-07 |
2003-12-22 |
The Brigham & Women's Hospital, Inc. |
Method and composition for inhibing or slowing blood coagulation
|
|
US7884083B2
(en)
|
2002-08-12 |
2011-02-08 |
Dynavax Technologies Corporation |
Immunomodulatory compositions, methods of making, and methods of use thereof
|
|
AU2003303524A1
(en)
*
|
2002-12-27 |
2004-07-29 |
La Jolla Pharmaceutical Company |
Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
|
|
WO2004089422A2
(en)
*
|
2003-03-30 |
2004-10-21 |
La Jolla Pharmaceutical Co. |
Methods of treating and monitoring systemic lupus erythematosus in individuals
|
|
US7771956B2
(en)
*
|
2003-06-30 |
2010-08-10 |
Brigham & Women's Hospital, Inc. |
Method for detecting the presence of a phospholipid
|
|
US9062392B2
(en)
*
|
2003-12-30 |
2015-06-23 |
Intel Corporation |
Methods for isolating a peptide methods for identifying a peptide
|
|
PL1794174T3
(pl)
|
2004-09-01 |
2012-11-30 |
Dynavax Tech Corp |
Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
|
|
CA2582940A1
(en)
|
2004-09-30 |
2006-04-06 |
Orico Limited |
Myostatin isoform
|
|
CA2591914C
(en)
*
|
2005-01-24 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
|
|
EP1874334A4
(en)
*
|
2005-04-15 |
2011-03-30 |
Vascular Biogenics Ltd |
COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
|
|
US9168286B2
(en)
*
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
KR20080074120A
(ko)
*
|
2005-10-13 |
2008-08-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
|
WO2007123765A2
(en)
*
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
BRPI0715072A2
(pt)
*
|
2006-08-03 |
2013-06-25 |
Orico Ltd |
antagonistas de miostatina
|
|
WO2009052148A1
(en)
*
|
2007-10-15 |
2009-04-23 |
California Institute Of Technology |
Functionalized polymers using protected thiols
|
|
EP2209896B1
(en)
|
2007-10-26 |
2017-03-01 |
Dynavax Technologies Corporation |
Methods and compositions for inhibition of immune responses and autoimmunity
|
|
EP2396035A4
(en)
*
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF THE B-LYMPHOCYTE STIMULATOR PROTEIN TO PROMOTE TRANSPLANT TOLERANCE
|
|
CN103153346A
(zh)
|
2010-06-16 |
2013-06-12 |
戴纳瓦克斯技术公司 |
使用tlr7和/或tlr9抑制剂的治疗方法
|
|
US9228184B2
(en)
|
2012-09-29 |
2016-01-05 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
CN105353137A
(zh)
*
|
2015-12-10 |
2016-02-24 |
中国农业科学院饲料研究所 |
一种快速检测色素苏丹红的方法
|
|
JP7117741B2
(ja)
*
|
2018-10-10 |
2022-08-15 |
国立大学法人 鹿児島大学 |
ＩｇＧ結合性ペプチドを含む固相担体及びＩｇＧの分離方法
|
|
WO2022197295A1
(en)
*
|
2021-03-17 |
2022-09-22 |
Milliken & Company |
Polymeric colorants with reduced staining
|